Hsiao D. Lieu - Nov 4, 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
SVP, Chief Medical Officer
Signature
David Woodhouse, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Nov 4, 2022
Transactions value $
$0
Form type
4
Date filed
11/8/2022, 08:07 PM
Previous filing
Mar 4, 2022
Next filing
Mar 6, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +150K $0.00 150K Nov 4, 2022 Common Stock 150K $5.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the shares subject to the option vest on each of November 4, 2023 November 4, 2024.